Advanced search
Publication Cover
Cancer Investigation Volume 35, 2017 - Issue 8
Submit an article Journal homepage
213
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC)

David R. SpigelSarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee, USA
,
Tarek M. MekhailFlorida Hospital Cancer Institute, Orlando, Florida, USA
,
David WaterhouseOncology Hematology Care/US Oncology, Cincinnati, Ohio, USA
,
Terence HadleyNorton Cancer Institute, Louisville, Kentucky, USA
,
Charles WebbBaptist Hospital East, Louisville, Kentucky, USA
,
Howard A. Burris IIISarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee, USA
,
John D. HainsworthSarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee, USACorrespondence[email protected]
&
F. Anthony GrecoSarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee, USA
 show all
Pages 541-546 | Received 10 Apr 2017, Accepted 16 Jun 2017, Published online: 01 Aug 2017

References

  • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med 2004;350:2129–2139.
  • Kwak EL, Bang Y-J, Camidge R, Solomon B, Maki RG, Ou SH, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693–1703.
  • Gavon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. New Engl J Med 2015;372:2018–2028.
  • Scagliotti GV, Parikh P, VonPawel J, Biesma B, Vansteenkiste J, Manegold E, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage, non-small-cell lung cancer. J Clin Oncol 2008;26:3543–3551.
  • Shepherd FA, Pereira JR, Ciuleanu J, Tan EH, Hirsh V, Thongpreasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–132.
  • Pirker R, Pereira JR, Szczesna A, Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009;373:1525–1531.
  • Amado RG, Wolf M, Peeters M, Van Custem E, Siena S, Freeman DJ, et al. Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626–1634.
  • Weiner LM, Belldegrun AS, Crawford J, Tolcher AE, Lockbaum P, Arends RH, et al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 2008;14:502–508.
  • Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008;358:1109–1117.
  • Eisenhauer E, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guidelines (version 1.1). Eur J Cancer 2009;45:228–247.
  • Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–98.
  • Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
  • Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895–2902.
  • Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized, double-blind, phase 3 study. Lancet 2009;374:1432–1440.
  • Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010:362;2380–2388.
  • Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label randomized phase 3 trial. Lancet Oncol 2012;13:239–246.
  • Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28:911–917.
  • Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, et al. Analysis of potential predictive markers of cetuximab benefit on BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:918–927.
  • O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, et al. Molecular biomarkers in NSCLC: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011;12:795–805.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.